Agilent Technologies (NYSE:A) Price Target Raised to $175.00

Agilent Technologies (NYSE:A) had its price target raised by research analysts at Morgan Stanley from $160.00 to $175.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s target price suggests a potential upside of 17.52% from the company’s current price.

A has been the subject of a number of other research reports. Bank of America raised Agilent Technologies from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $150.00 to $145.00 in a research report on Thursday, May 28th. Sanford C. Bernstein began coverage on Agilent Technologies in a research report on Friday, June 26th. They set an “outperform” rating and a $155.00 target price on the stock. Wells Fargo & Company decreased their price target on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Barclays lifted their price target on Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Finally, Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $160.24.

Agilent Technologies Trading Down 0.4%

Shares of A traded down $0.58 on Wednesday, hitting $148.91. 289,723 shares of the stock traded hands, compared to its average volume of 2,224,047. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $42.06 billion, a P/E ratio of 29.90, a P/E/G ratio of 2.64 and a beta of 1.25. The stock’s 50 day moving average is $134.70 and its two-hundred day moving average is $125.23. Agilent Technologies has a 1 year low of $108.35 and a 1 year high of $160.27.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. The firm had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, sell-side analysts predict that Agilent Technologies will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors have recently bought and sold shares of A. State Street Corp raised its stake in shares of Agilent Technologies by 1.9% in the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after acquiring an additional 241,029 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Agilent Technologies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock valued at $1,006,519,000 after acquiring an additional 25,139 shares in the last quarter. Deutsche Bank AG boosted its position in Agilent Technologies by 17.1% during the 2nd quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after purchasing an additional 1,024,516 shares during the period. Bank of New York Mellon Corp increased its holdings in Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after purchasing an additional 2,440,360 shares in the last quarter. Finally, Morgan Stanley increased its holdings in Agilent Technologies by 15.9% in the 4th quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock valued at $686,049,000 after purchasing an additional 692,202 shares in the last quarter. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.